David Meiri, PhD, is Associate Professor at the Faculty of Biology at the Technion and a member of the Technion Integrated Cancer Center (TICC). Dr. Meiri holds a M.Sc. in Biochemistry and a Ph.D. in plant biotechnology from Tel Aviv University. He conducted his post-doctoral fellowship at the Ontario Cancer Institute where he focused on tumor invasion and metastasis.
During his post-doctoral studies, he expanded his knowledge in human biology and cancer pathogenesis and gained worldwide recognition as an expert in the fields of G-protein coupled receptors (GPCRs), small GTPases and cytoskeleton. Upon completion of his post-doctoral fellowship, Dr Meiri took a position at the Technion Israel Institute of Technology, where he heads the "Laboratory of Cancer Biology and Cannabinoid Research".
Presently, his lab investigates the therapeutic potential of phytocannabinoids, with focus on the antitumor effects of cannabinoids.
In addition to the laboratory cannabis research performed on-site, Dr. Meiri collaborates with cannabis growers, clinicians, major manufacturers and distributors of medical cannabis for the purpose of revolutionizing cannabis treatment. He is operating the "Cannabis Database Project" and his lab is currently involved in eight clinical trials covering diverse aspects of cannabis treatment such as colon disease, pain prevention, cancer treatment and epilepsy.